News
Complex protein interactions at synapses are essential for memory formation in our brains, but the mechanisms behind these processes remain poorly understood. Now, researchers have developed a ...
Science Featured on MSN7d
Key Protein Glycosylation Found to Drive Lung Cancer's Deadly Resistance to DrugsRecent research sheds light on how changes in the chemical structure of a protein called Interleukin-6 affect lung cancer’s ...
One key pathway is the soluble guanylyl cyclase–cyclic GMP–protein kinase G system ... interesting is the role of nitric oxide as a Janus molecule in the cell death or survival mechanisms ...
Janus Henderson and Guardian Life have forged a strategic partnership that will see the asset manager take on the life insurer’s $45 billion investment grade fixed income portfolio. And the deal ...
The partnership is set to close by Q3 2025. The move will see Janus Henderson manage the $45 billion investment grade public fixed income portfolio for Guardian’s general account, as well as more than ...
Guardian Life’s internal fixed-income investment staff will join Janus Henderson, which will now manage the insurer’s $45 billion investment-grade fixed-income portfolio. Janus Henderson and the ...
The Guardian Life Insurance Company of America® one of America’s largest life insurers and a leading provider of employee benefits, and Janus Henderson Group plc, have announced an innovative ...
Studies have shown that ginseng and its functional components have the ability to regulate lipid metabolism disorders, inflammation, oxidative stress, endoplasmic reticulum stress, insulin resistance, ...
The city on Monday said it appeared the makeshift structure — which has since been taped off — had not been installed by the city parks department. But News 8 has since confirmed that it was ...
RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...
He also highlighted upadacitinib and abrocitinib, the oral Janus kinase inhibitors for AD. “Being able to really sit down with colleagues and figure out how are we going to use these things when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results